Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb 18:2022:1817694.
doi: 10.1155/2022/1817694. eCollection 2022.

The Expression and Clinical Significance of PCNAP1 in Hepatocellular Carcinoma Patients

Yanhong Chen  1 , Jiao Zhang  1 , Jia Liu  1 , Jianguo Wang  1 , Chao Shi  1 , Lu Lu  1 , Xing Cheng  1 , Guoping Niu  1 , Shuangshuang Zhang  1
Affiliations

The Expression and Clinical Significance of PCNAP1 in Hepatocellular Carcinoma Patients

Yanhong Chen et al. J Immunol Res. .

Abstract

Background: Long noncoding RNAs (lncRNAs) play an important role in many cancer progression. The aim of this study was to evaluate the expression level and clinical significance of the lncRNA, proliferating cell nuclear antigen pseudogene 1 (PCNAP1), in cancer tissue and the plasma of patients with hepatocellular carcinoma (HCC).

Methods: Quantitative real-time polymerase chain reaction was used to detect the expression of PCNAP1 in HCC tissue, adjacent tissue, and plasma. Spearman's rank correlation analysis was performed to assess relationships among cancer tissue, plasma PCNAP1, and plasma AFP. Kaplan-Meier analysis was used to assess survival of HCC patient with high and low expression of PCNAP1. The survival difference was compared by the log-rank test. The use of plasma levels PCNAP1 for diagnosing HCC was evaluated by receiver operating characteristic curve analysis.

Results: The expression of PCNAP1 in HCC tissue was significantly higher than in adjacent tissue (P < 0.01). The PCNAP1 levels were related to the TNM stage, lymph node metastasis, and tumor maximum diameter (P < 0.05) but were not related to gender and age (P = 0.459 and 0.656). Patients with greater levels of PCNAP1 had poorer survival than patients with lower levels of expression (P < 0.01). Compared to the healthy control group, a gastric cancer group, and a colorectal cancer group, HCC patient plasma levels of PCNAP1 were significantly greater (P < 0.01). The area under the curve (AUC) of plasma PCNAP1 in HCC patients was 0.83 (95% CI: 0.78-0.88). With a cut-off value of plasma PCNAP1 at 1.27, an HCC diagnostic sensitivity of 70.08%, and a specificity of 85.04%, was the maximum diagnostic efficiency achieved.

Conclusion: This study demonstrates PCNAP1 levels to be increased in HCC patients. As such, PCNAP1 may be a new tool useful in disease diagnosis and prognosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there is no conflict of interest regarding the publication of this paper.

Figures

Figure 1
Figure 1
(a) The relative levels of PCNAP1 were examined by RT-qPCR in HCC cancer tissue and adjacent tissue. (b) The relationship between PCNAP1 expression and survival by Kaplan–Meier analysis.
Figure 2
Figure 2
Relative levels of PCNAP1 in plasma of HCC patients, healthy controls, gastric cancer, colorectal cancer, and disease subjects were examined by RT-qPCR.
Figure 3
Figure 3
Spearman's rank correlation analysis was taken for analysis of the relationship between tissue and plasma PCNAP1 and (a) cancer tissue and (b) plasma AFP in HCC patients.
Figure 4
Figure 4
ROC curve analysis of the use of plasma PCNAP1 for diagnosis and differential diagnosis of hepatocellular carcinoma.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Bray F., Ferlay J., Soerjomataram I., Siegel R. L., Torre L. A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a Cancer Journal for Clinicians . 2018;68(6):394–424. doi: 10.3322/caac.21492. - DOI - PubMed
    1. Wu L., Cao K. X., Ni Z. H., et al. Rhein reverses doxorubicin resistance in SMMC-7721 liver cancer cells by inhibiting energy metabolism and inducing mitochondrial permeability transition pore opening. BioFactors . 2019;45(1):85–96. doi: 10.1002/biof.1462. - DOI - PubMed
    1. Fang K. C., Kao W. Y., Su C. W., et al. The prognosis of single large hepatocellular carcinoma was distinct from Barcelona clinic liver cancer stage A or B: the role of albumin-bilirubin grade. Liver Cancer . 2018;7(4):335–358. doi: 10.1159/000487407. - DOI - PMC - PubMed
    1. Omata M., Cheng A. L., Kokudo N., et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatology International . 2017;11(4):317–370. doi: 10.1007/s12072-017-9799-9. - DOI - PMC - PubMed
    1. Villanueva A. Hepatocellular carcinoma. The New England Journal of Medicine . 2019;380(15):1450–1462. doi: 10.1056/NEJMra1713263. - DOI - PubMed

MeSH terms